Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Physiol Heart Circ Physiol ; 304(6): H806-15, 2013 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-23335797

RESUMO

Hemorrhagic transformation is an important complication of acute ischemic stroke, particularly in diabetic patients receiving thrombolytic treatment with tissue plasminogen activator, the only approved drug for the treatment of acute ischemic stroke. The objective of the present study was to determine the effects of acute manipulation of potential targets for vascular protection [i.e., NF-κB, peroxynitrite, and matrix metalloproteinases (MMPs)] on vascular injury and functional outcome in a diabetic model of cerebral ischemia. Ischemia was induced by middle cerebral artery occlusion in control and type 2 diabetic Goto-Kakizaki rats. Treatment groups received a single dose of the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(4-sulfonatophenyl)prophyrinato iron (III), the nonspecific NF-κB inhibitor curcumin, or the broad-spectrum MMP inhibitor minocycline at reperfusion. Poststroke infarct volume, edema, hemorrhage, neurological deficits, and MMP-9 activity were evaluated. All acute treatments reduced MMP-9 and hemorrhagic transformation in diabetic groups. In addition, acute curcumin and minocycline therapy reduced edema in these animals. Improved neurological function was observed in varying degrees with treatment, as indicated by beam-walk performance, modified Bederson scores, and grip strength; however, infarct size was similar to untreated diabetic animals. In control animals, all treatments reduced MMP-9 activity, yet bleeding was not improved. Neuroprotection was only conferred by curcumin and minocycline. Uncovering the underlying mechanisms contributing to the success of acute therapy in diabetes will advance tailored stroke therapies.


Assuntos
Curcumina/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Infarto da Artéria Cerebral Média/tratamento farmacológico , Inibidores de Metaloproteinases de Matriz/uso terapêutico , Metaloporfirinas/uso terapêutico , Minociclina/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Animais , Diabetes Mellitus Tipo 2/genética , Edema/tratamento farmacológico , Hemorragia/tratamento farmacológico , Infarto da Artéria Cerebral Média/complicações , Infarto da Artéria Cerebral Média/patologia , Locomoção , Masculino , Metaloproteinase 9 da Matriz/metabolismo , NF-kappa B/antagonistas & inibidores , Ácido Peroxinitroso/antagonistas & inibidores , Ratos , Ratos Mutantes , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA